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Meijuan Huang1,2 and Youling Gong1,2*Abstract
Purpose: To evaluate the treatment outcome of salvage concurrent radio-chemotherapy for patients with loco-
recurrent esophageal cancer after surgery.
Methods: 50 patients with loco-recurrent squamous-cell cancer after curative esophagectomy were retrospectively
analyzed. Patients were treated with radiotherapy (median 60 Gy) combined with chemotherapy consisting of
either 5-fluorouracil (5-FU) plus cisplatin (DDP) (R-FP group) or paclitaxel plus DDP (R-TP group).
Results: The median follow-up period was 16.0 months. The 1-year and 3-year survival rates were 56% and 14%,
respectively. The median progression-free survival (PFS) and overall survival (OS) time was 9.8 and 13.3 months
respectively. There was no statistical significance of the PFS of the two groups. The OS (median 16.3 months) in the
R-TP group was superior to that in the R-FP group (median: 9.8 months) (p= 0.012). Among the patients who had
received ≥60 Gy irradiation dose, the median PFS (10.6 months) and OS (16.3 months) were significantly superior to
the PFS (8.7 months) and OS (11.3 months) among those patients did not (all p< 0.05). Grade 3 treatment-related
gastritis were observed in 6 (27.3%) and 7 (25%) patients in the R-FP and R-TP group respectively. By univariate
survival analysis, the age (<60 years), TP regimen and higher irradiation dose might improve the OS of such
patients in present study.
Conclusions: For those patients with post-operative loco-recurrent squamous-cell esophageal carcinoma,
radiotherapy combined with either FP or TP regimen chemotherapy was an effective salvage treatment. Younger
age, treatment with the TP regimen and an irradiation dose ≥60 Gy might improve the patients’ treatment
outcome.
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Treatment outcomes, ToxicityIntroduction
Curative esophagectomy with radical lymph node dissec-
tion is the primary treatment for early stage esophageal
carcinoma [1,2]. However, the 5-year survival rate remains
only around 40% [3]. Loco-regional recurrence still is the
major type of failure in those patients following surgery* Correspondence: gongyouling@gmail.com
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reproduction in any medium, provided the or[4,5]. Depending on performance status, there are a
number of patients which might tolerate the salvage treat-
ment. In these patients, a potential for cure still exists.
Since 2000, radiotherapy, chemotherapy or chemo-
radiotherapy have been demonstrated as the possible
salvage treatment for post-operative local recurrent
esophageal carcinoma, with reported the median OS of
7.0-16.0 months [6-16]. In a phase II trial, Jingu et al.
from Japan reported that radiotherapy (60 Gy/30 frac-
tions) combined with nedaplatin and 5-FU is a safe and
effective salvage option for loco-recurrent esophageal
carcinoma, achieving an impressive median OS of
39 months [17].Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Basic and clinical characteristics of the patients in
present study (n = 50)
Characteristics Number of patients (%)
Age (years)
Median (range) 54 (39–64)
Gender









Time form surgery to recurrences (months)
Median (range) 13.0 (5.0-32.0)
Sites of recurrencec
Anastomotic 7 (14.0)
Supraclavicular lymph nodes 18 (36.0)
Mediastinal lymph nodes 15 (30.0)
Abdominal lymph nodes 5 (10.0)
Supraclavicular/mediastinal lymph nodes 4 (8.0)
Supraclavicular/abdominal lymph nodes 1 (2.0)
a: Eastern Cooperative Oncology Group; b: Staging system, 6th edition,
American Joint Committee on Cancer, 2002; c: 4 patients with supraclavicular
and mediastinal lymph nodes recurrence, 1 patients with mediastinal and
abdominal lymph nodes recurrence.







R-TP group 5 (17.9%) 15 (53.6%) 8 (28.3%)
R-FP group 5 (22.7%) 11 (50.0%) 6 (27.3 %)
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esophageal carcinoma and good performance status
could be considered as the potentially curative ones.
Radio-chemotherapy consisting of fluorouracil (5-FU)/
DDP (FP) or paclitaxel/DDP (TP) regimen has been used
as the salvage and definitive treatment in our practice,
according to the National Comprehensive Cancer Net-
work (NCCN) Guidelines [18].
In this study, we retrospectively evaluated the survival
of the identical patients treated with salvage concurrent
radio-chemotherapy, in order to analyze the impacts of
the chemotherapy regimen (FP or TP) and the irradiation
dose on the treatment outcome of post-operative local
recurrences of squamous-cell esophageal carcinoma.
Patients and methods
Patients’ data
A loco-regional recurrence was defined as anastomotic
recurrence or lymph node metastasis in supraclavicular
and mediastinum regions; only in patients with an initial
diagnosis of lower thoracic carcinoma, the abdominal
lymph node metastasis was considered as local recur-
rences. Between March 2005 and December 2009, a total
of 50 esophageal carcinoma patients received chemo-
radiotherapy for loco-regional recurrence at West China
hospital and Second Affiliated Hospital of Anhui Med-
ical University. Each patient had undergone an R0 resec-
tion including extended lymph node dissection and had
histologically proven squamous-cell eaophageal carcin-
oma. All of the patients gave their informed consent be-
fore treatment, which was in accordance with the
Declaration of Helsinki [19] and also approved by the
Ethics Committee of our hospitals.
The basic and clinical characteristics of the studied
patients are summarized in Table 1. The median age of
the patients was 54.2 years (range: 39-64 years); most of
them were male and with the Eastern Cooperative Oncol-
ogy Group (ECOG) performance status score 0-1 (47/50,
94.0%). The initial tumor stage (Staging system, American
Joint Committee on Cancer) [20] after surgery in the
present study were 17 stage I-II and 33 stage III-IV
respectively. The median time between surgery and recur-
rence was 13.0 months (range: 5.0-32.0 months). Local
recurrence was diagnosed by computed tomography
(CT), upper gastrointestinal endoscopy and ultrasonog-
raphy. There were 7 (12.7%), 23 (41.8%), 19 (34.5%) and
6 (10.9%) recurrences in anastomotic, supraclavicular, medi-
astinal and abdominal regions respectively, and 5 patients
were confirmed having 2 recurrent sites respectively.
Salvage radio-chemotherapy
Radiotherapy
All patients underwent initial CT simulation, then the
three-dimentional conformal radiotherapy (3D-CRT) andwere usually applied for treament. Intensity-modulated
radiotherapy (IMRT) was used if any supraclavicular
lymph node was included as a target. The gross tumor
volume (GTV) included all known gross disease as deter-
mined by the imaging and endoscopic findings. The clin-
ical target volume (CTV) was defined as the GTV plus a
2-3 cm radial margin. If the target was coutoured in the
supraclavicular region, the correlated lymphatic drainage
regions was coutoured as the CTV, extending to the
cricothyroid membrane. The planning target volume
(PTV) was defined as the CTV plus a 0.5 cm margin in
all direction, respectively. The patients received a
conventional-fraction schedule: 1.8-2.0 Gy per fraction
and 5 fractions per week with a 6-MV linear accelerator.
As shown in Table 2, the median irradiation dose for
the PTV was 60 Gy, with a range of 50.4-64 Gy. The
dose constraint for the spinal cord was a maximum dose
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within 15 Gy and 30% respectively.
Chemotherapy
The chemotherapy and radiotherapy started at the same
day. The regimens consisting of either 5-FU 500 mg/m2/day
for five days plus DDP 75 mg/m2 on day one per 4 weeks
or paclitaxel 135 mg/m2 and DDP 75 mg/m2 on day one
per 3 weeks. Only the grade 3 or higher treatment-
related esophagitis were observed and if prolonged, the
chemotherapy was discontinued; otherwise the chemo-
therapy was suspended until recovery and reduced the
regimen dose by 25% in the subsequent cycle.
Treatment assessment
Evaluation of treatment response was carried out
according to Response Evaluation Criteria in Solid
Tumors (RECIST criteria) [21]. Disappearance of the all
GTVs was designated to indicate complete response
(CR) on CT persisting for more than 4 weeks. A partial
response (PR) was defined as a minimum of a 30%
decrease in the sum of the longest diameter of target
lesions. A disease was defined stable (SD) where there
was neither a sufficient shrinkage to qualify for a PR nor
a sufficient increase in the target lesions, and progressive
(PD), when there was at least a 20% increase in the sum
of the longest diameter of the target lesions or appear-
ance of new lesions. Follow-up evaluations were per-
formed every 2 to 3 months for the first year and every
6 months thereafter by CT.
Toxicities were evaluated according to the National
Cancer Institute Common Toxicity Criteria version 3.0.
Statistical methods
Statistical analyses were performed using the SPSS soft-
ware (version 13.0). The progression-free survival (PFS)
time was measured from the date the treatment began
to the date of the disease progression and the overall
survival (OS) time was considered from the start of
treatment to date of data analysis or date of loss from
follow-up for patients alive. Patients without disease
relapse or progression who discontinued the study for
any reason were censored at the last on study tumor
assessment date. The rates of PFS and OS curves
depending on the different factors were calculated using
the method of Kaplan-Meier analysis and were compared
using a log-rank test. A p value< 0.05 was considered
with statistical significance. Also, Cox's proportional
hazards regression model was used for univariate survival
analysis. Patient age, gender, staging after surgery, time
interval between surgery and recurrence, irradiation dose,
chemothrapy regimen, tumor response to treatment were
put into univariate analysis. Due to the small patient
numbers, multivariate analysis was not performed.Results
The median follow-up time for the studied patients was
16.0 months (range: 10.0-44.0 months) and the median
time interval between surgery and recurrence was
13.0 months (range: 5.0-32.0 months). All patients com-
pleted the radiotherapy treatment. In present study,
72.7% (16/22) and 75% (21/28) patients had received
2 cycles of chemotherapy in the FP and TP group
respectively. And the remaining patients had received
at least 1 cycle of chemotherapy.
Responses to treatment
All patients were assessed as having had a response
(details shown in Table 2). In the R-FP group, 5 (22.7%),
11 (50%) and 6 (27.3%) patients showed CR, PR and SD,
respectively. And in the R-TP group, these numbers
were 5 (17.9%), 15 (53.6%) and 8 (28.3%) respectively.
The overall responses were 72.7% (16/22) and 71.7%
(20/28) in the R-FP and R-TP group respectively.
Follow-up
Patient follow-up studies continued until December
2011, with no one lost to follow-up. The 1-year and 3-
year survival rates were 56% and 14% respectively. The
median PFS of the whole group was 9.8 months (range:
4.7-41.0 months) and the median OS of all patients was
13.3 months (range: 5.4-44.0 months).
In sub-group analysis, the median PFS and OS
were 9.8 months [95% confidential interval (CI) 9.4-
10.1 months] and 9.8 months (95% CI 9.4-10.2 months)
in the R-FP group respectively (Figure 1). The patients
receiving the TP regimen had the similar outcomes
of the PFS (9.8 months, 95% CI 7.5-12.0 months) but a
significant improvement of the OS (16.3 months, 95% CI
14.5-18.1 months) (p=0.012), compared to those patients
receiving the FP regimen.
In addition, the irradiation dose had a clear impact
on the treatment outcomes in these evaluated patients
(Figure 2). Patients receiving more than 60 Gy irradi-
ation dose had significantly prolonged period in PFS
(10.6 months, 95% CI 7.8-13.3 months) and OS
(16.3 months, 95% CI 13.6-18.9 months) than those
patients who received an irradiation dose less than
60 Gy (for PFS: 8.7 months, 95% CI 6.5-10.8 months and
for OS: 11.3 months, 95% CI 9.3-13.2 months) respect-
ively (p= 0.01 and 0.04, respectively).
Treatment-related toxicities
All the patients were evaluated for tretment-related toxi-
cities (Table 3). The combination of radiotherapy and
chemotherapy (either FP or TP regimens) were proved
to be tolerable. The most common toxicities were the
treatment-related gastritis and neutropenia. Grade 3
treatment-related gastritis were observed in 6 patients
Figure 1 Kaplan-Meier analysis of progression-free survival (PFS) and overall survival (OS) in the present study, according to the
chemotherapy regimen the patients received.
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group, respectively. Grade 3 neutropenia were observed
in 7 (31.8%) and 6 (26.4%) patients in the R-FP and R-TP
group, respectively. The other major grade 2 toxicities
included the neutropenia, anemia and nausea/vomiting/
diarrhea. One patient receiving R-TP treatment had the
grade 3 vomiting (3.6%). No grade 4 or 5 toxicity was
recorded among all the patients.
Univariate survival analysis
Due to the small number of the evaluated, only the uni-
variate analysis was performed according to the basic
and clinical characteristics of the patients. The details
were shown in Table 4. The gender, disease stage after
surgery, the responses to the treatment and irradiation
dose did not significantly affected the survival time.
While the patients’ age (<60 years), the chemotherapy
regimen (TP) and irradiation dose more than 60 GyFigure 2 Kaplan-Meier analysis of progression-free survival (PFS) and
irradiation dose the patients received.showed the trends which could improve the overall sur-
vival of the patients in present study respectively
(p= 0.048, 0.025 and 0.041, respectively).
Discussion
Loco-regional recurrences after intial surgery in patients
with esophageal cancer remain a serious challenge to
clinical oncologists. The NCCN Guidelines pointed out
that a highly selected group of patients with local-
regional tumor recurrence after initial surgery may be
considered fit and able to tolerate concurrent radio-
chemotherapy with a potential for cure [18]. In a line
with the previous studies, our data indicated that salvage
concurrent radio-chemotherapy was an active and prom-
ising treatment strategy for such patients, reaching a
median OS of 13.3 months with tolerable side-effects.
The present protocol of concurrent radio-chemotherapy
was completed in 74% (37/50) of the patients, and nooverall survival (OS) in the present study, according to the
Table 3 Treatment-related toxicities (number = 22 and 28 in R-FP and R-TP group respectively)a
Toxicities Toxicity grades, n (%)
Grade 1 Grade 2 Grade 3
Hematological
Neutropenia 3 (13.6)/5 (17.9) 12 (54.5)/17 (60.7) 7 (31.8)/6 (21.4)
Anemia 8 (36.4)/10 (35.7) 14 (63.6)/18 (64.3) 0/0
Thrombocytopenia 17 (77.3)/18 (64.3) 5 (22.7)/10 (35.7) 0/0
Non-hematological
Digestive tract side-effectsb 3 (13.6)/7 (25) 19 (86.4)/20 (71.4) 0/1 (3.6)
Treatment-related esophagitis 2 (9.1)/3 (10.7) 14 (63.6)/18 (64.3) 6 (27.3)/7 (25.0)
a: Data presented as number in the R-FP group (%)/number in the R-TP group (%); b: Including nausea, vomiting and diarrhea.
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tumor response rate was nearly 72% in R-TP and R-FP
group respectively, with a 3-year survival rate of 14%.
These results are very similar to those reported in previ-
ous studies [13,15]. Yamashita et al. [13] reported the
results of radiotherapy with or without chemotherapy at
an average total dose of 56.6 Gy. The median survival time
was 13.8 months and 1-year survival rate was 56% in
patients with patients with loco-regional recurrence of
esophageal cancer after curative surgery. Recently, Baxi
et al. from Princess Alexandra Hospital reported their
treatment outcomes using DDP and 5-FU plus radiother-
apy (range: 45–60 Gy) for recurrent esophageal cancer
[15]. The 2-year survival rate of all patients was 21% and
the median OS was 16 months. While the very impressive
results of salvage radio-chemotherapy for such patients
were reported by Jingu et al. [17] and the 3-year survival
rate was 56.3% using radiotherapy combined with nedapla-
tin and 5-FU. But it was a small phase II study (patients’
number= 30), and these data had not been confirmed by
further clinical investigations.Table 4 Prognostic factors by log-rank test and univariate su
Factors Group Number




Staging after surgery I/II 17
III/IV 33
Chemotherapy regimen TP 28
FP 22
Response to treatment CR/PR 40
SD 10
Irradiation dose ≧60 Gy 29
< 60 Gy 21
a: Cox's proportional hazards regression model; b: Overall survival.By sub-group analysis in the present study, the median
OS of the 28 patients received R-TP regimen
(16.3 months) was significantly superior than that of
other patients who received R-FP regimen (9.8 months)
(p< 0.05). According to our knowledge, there was no
direct comparison between FP and TP regimen when
combined with radiotehrapy in the definitive treatment
for esophageal cancer. Recently, Ajani et al. reported
that the regimen including 5-FU/DDP/paclitaxel with
50.4 Gy of radiation was associated with high morbidity,
although it reached a 1-year survival rate of 75.7% in
RTOG 0113 trial [22]. So far, FP regimen still was the
first choice in definitive radio-chemotherapy for esopha-
geal cancer in the NCCN guidelines [18]. The possible
reason that the poorer treatment outcomes using R-FP
regimen in present study was the relative lower dosage
of 5-FU (500 mg/m2/D, D1-5 per 4 weeks). In the trial
INT 0123, Minsky et al. established the standard dos-
age of 5-FU (1000 mg/m2/D, D1-4 per 4 weeks) in the
definitive radio-chemotherapy for esophageal cancer
[23]. However, considering the relative smaller body sizervival analysisa in present study
Median OSb
(months)
Log-rank test Univariate analysis
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sequently decreased, similar in methodology with other
Asian studies [12,17].
In addition, our data indicates that an irradiation dose
of more than 60 Gy could improve not only the PFS but
the OS among those patients with recurrent esophageal
cancer after surgery (both p< 0.05). In our opinion,
50.4 Gy was the standard irradiation dose for esophageal
cancer reported by Minsky et al. [23] in trial INT 0123
and the higher radiation dose (64.8 Gy) did not increase
the survival or local/regional control. But the authors
also pointed out that 63.6% (7/11) the treatment-related
deaths in the high-dose arm occurred in patients who
received 50.4 Gy or less, and the higher dose of irradi-
ation might not be responsible for the increased mortal-
ity. In 2001, reports from Nemoto et al. [8] indicated
that no significance between the patients’ survival
received more than or less than 60 Gy. But the 1-year
and 3-year survival rates were 45% and 20% in the
higher dose arm respectively, which were superior
than those of the lower dose arm (15% and 7% respect-
ively). In the study by Baxi et al. [15] most patients
(79%, 11/14) received irradiation dose of 58–60 Gy and
the median OS (16 months) of all patients was encour-
aging. And in study by Jingu et al. [17], the irradiation
dose was 60 Gy/30 fractions and the treatment out-
comes (median OS of 39 months) were extremlly excit-
ing. To data, one study has indicated that the survival
was similar among the patients received an irradiation
dose more or less than 60 Gy [14]. After a careful review
of the literatures, the suitable irradiation dose for recur-
rent esophageal cancer remains unclear and requires
further investigations.
With regard to the side-effects of concurrent radio-
chemotherapy for post-operative esophageal cancer, the
irradiation dose for the esophago-gastric anastomosis
and the gastric tube should be of particularly concerm.
In the present study, grade 3 treatment-related gastritis
were recorded in 6 patients (27.3%) and 7 patients
(25.0%) in the R-FP and R-TP group, respectively. One
patient received R-TP treatment was observed having
the grade 3 vomiting. As far as we know, the prediction
probability of the normal tissue complication at 5%
within 5 years after radiotherapy (TD 5/5) of the stom-
ach is 60 Gy [24]. Furthermore, Nemato et al. [8]
reported that one patient died of necrosis of the stomach
6 months after comletion of radiation therapy (66 Gy).
Therefore, we avoided prescribing a dose of more than
60 Gy to the recurrence of the anastomotic sites in
present study, and only recurrences of the regional
lymph nodes received the irradiation dose more than
60 Gy. As a result, no serious treatment-related side-
effects (gastric fistula or necrosis) were observed in the
follow-up. Other common toxicities included hematologicalside-effects (neutropenia and anemia) and digestive tract
toxicities in present study. Compared to the previous
studies of patients with the locally-advanced esophageal
cancer [22,23,25-27], the treatment-related toxicities of
the concurrent radio-chemotherapy in present study
were similar to or less than the studies mentioned above
[8,12-15,17].
One issue should be mentioned here. According to the
NCCN guidelines [18], also as summarized by two meta-
analysis [28,29], the pre-operative chemoradiation fol-
lowed by surgery is the most common strategy for
patients with resectable esophageal cancer in Western
countries, which could significantly improve the 3-year
OS and reduce the loco-reginal recurrences. The irradi-
ation dose in such approach is nearly 40-45 Gy. Thus,
the patient who received the pre-operative chemoradia-
tion could not be treated with such higher irradiation
dose similarly to the present study (around 60 Gy) for
loco-regional recurrence. The optimal treatment strat-
egies for this specific group of patients need further clin-
ical studies.
In conclusion, combination of radiotherapy with con-
current FP or TP chemotherapy is a safe and promis-
ing salvage treatment for loco-regional recurrence of
esophageal cancer after surgery. The use of TP regimen
and an irradiation dose of more than 60 Gy may
improve the overall survival of these patients. However,
the optimal treatment strategy (irradiation dose and
chemotherapy regimen) for loco-regional recurrent
esophageal cancer warrents further studies.
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